Zotatifin combined with platinum for advanced triple negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called zotatifin, which may help slow or stop the growth of advanced triple negative breast cancer. The study combines it with a type of chemotherapy (called platinum) to see if this works when other treatments haven't.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple negative breast cancer (ER <1%, PR <1%, HER2 negative), and it has spread or come back and standard treatments no longer work.
- If your cancer is not inflammatory, you must have already received at least 2 lines of treatment for metastatic disease. If you have inflammatory breast cancer, there is no limit on how many treatments you have had.
- You must be 18 years or older.
- You must have at least one tumor that can be measured on imaging.
- You must be in reasonably good health, with adequate organ and marrow function (like blood counts and liver/kidney function).
- You must not have certain lung conditions, active infections (like hepatitis B or C, HIV unless well-controlled), or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called retlirafusp alfa, which may boost the immune system, when combined with chemotherapy or another drug (fuzuloparib) for people with triple-negative breast cancer that has spread or come back, or is at high risk of coming back. The goal is to see if the combination helps shrink tumors or prevents cancer from returning.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy, compared to chemotherapy alone, for people with triple-negative breast cancer that has spread and hasn't been helped by earlier treatments. The goal is to see if adding this immunotherapy can shrink tumors or slow the cancer's growth better than chemotherapy alone.
Hear when a new Phase IB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.